New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
10:03 EDTOIS, HEINY, CNC, AGN, TPLM, PHH, MWV, DANOY, CSH, AEIS, TSLX, OXLC, KOS, CLVS, BRCM, GRA, ZQKOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Advanced Energy (AEIS) downgraded to Hold from Buy at Needham... Allergan (AGN) downgraded to Neutral from Outperform at Credit Suisse... Broadcom (BRCM) downgraded at Stifel... Cash America (CSH) downgraded to Neutral at Janney Capital... Centene (CNC) downgraded to Sell from Neutral at Citigroup... Clovis (CLVS) downgraded to Neutral from Buy at Citigroup... Danone (DANOY) downgraded to Sell from Neutral at Goldman... Heineken (HEINY) downgraded to Sell from Neutral at Goldman... Kosmos (KOS) downgraded to Neutral from Accumulate at Global Hunter... MeadWestvaco (MWV) downgraded to Neutral from Buy at Buckingham... Oil States (OIS) downgraded to Neutral from Positive at Susquehanna... Oxford Lane (OXLC) downgraded to Neutral from Buy at Ladenburg... PHH Corp. (PHH) downgraded to Neutral from Buy at Compass Point... Quiksilver (ZQK) downgraded at Monness Crespi... TPG Specialty Lending (TSLX) downgraded to Market Perform at Wells Fargo... Triangle Petroleum (TPLM) downgraded to Neutral from Buy at Global Hunter... W.R. Grace (GRA) downgraded to Buy from Conviction Buy at Goldman.
News For AEIS;AGN;BRCM;CSH;CNC;CLVS;DANOY;HEINY;KOS;MWV;OIS;OXLC;PHH;ZQK;TSLX;TPLM;GRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 31, 2015
07:39 EDTAGNCiti calls Allergan a 'stock to own,' keeps $360 target
Citi analyst Liav Abraham calls Allergan a "stock to own" given its "attractive" organic growth profile, pipeline potential and ability to do more acquisitions. He reiterates a Buy rating on the stock with a $360 price target.
August 28, 2015
09:50 EDTAGNAllergan plans for generic version of Endo's Fortesta blocked, Bloomberg reports
A judge upheld Endo's (ENDP) patents on Fortesta expiring in 2018 and blocked Allergan's (AGN) bid to launch a generic version of the testosterone gel, according to Bloomberg.
August 26, 2015
16:04 EDTOXLCOxford Lane authorizes new $20M stock repurchase program
Subscribe for More Information
August 25, 2015
08:14 EDTAGNAllergan multiple is low, says Leerink
Leerink predicts that Allergan's 2016 EPS will come in at $17-$18. The firm thinks the company has "durable revenue streams," and a "deep pipeline with several potential blockbuster candidates." Leerink adds that the company "has significant capacity for M&A." It keeps a $388 price target and Outperform rating on the shares.
08:05 EDTCSHCash America management to meet with Jefferies
Subscribe for More Information
August 24, 2015
08:37 EDTAGNAllergan recalls certain lots of REFRESH, FML, Blephamide treatments
Allergan announced that it is conducting a voluntary recall down to consumer level of specific lots of its REFRESH Lacri-Lube 3.5g and 7g for dry eye, REFRESH P.M. 3.5g for dry eye, FML 0.1%, and Blephamide 10%/0.2% sterile topical ophthalmic ointment combining an antibacterial and a corticosteroid, 3.5g. Allergan chose to initiate this recall based on a small number of customer complaints which reported a small black particle at the time of use. Allergan has informed the U.S. Food and Drug Administration of this voluntary recall. Allergan is contacting retailers and wholesalers who have been shipped affected product lots to initiate the recall and is informing them of the steps needed to return affected product.
06:22 EDTBRCMTSMC pursuing 16nm chip orders, DigiTimes reports
According to market sources, DigiTimes reports that TSMC (TSM) has been "actively" seeking 16nm FinFET chip orders. In addition to securing a portion of Apple's (AAPL) A9 chip orders, TSMC has also received orders from AMD (AMD), Broadcom (BRCM), LG, Nvidia (NVDA) and Avago (AVGO), the sources say, noting that TSMC failed to maintain orders for Qualcomm's (QCOM) flagship mobile chips, as it has placed orders for the Snapdragon 820 series with Samsung (SSNLF). Reference Link
August 21, 2015
13:45 EDTOXLCOxford Lane comments on upcoming stock distribution
Subscribe for More Information
10:02 EDTOXLCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:23 EDTOXLCOxford Lane downgraded to Neutral from Buy at Ladenburg
Ladenburg analyst Mickey Schleien downgraded Oxford Lane Capital to Neutral.
August 20, 2015
10:00 EDTOISOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:00 EDTBRCMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:39 EDTBRCMBroadcom downgraded to Hold from Buy at Argus
Argus downgraded Broadcom (BRCM) to Hold following the announcement that the waiting perorid under the Hart-Scott-Rodino Antitrust Act had expired. The firm now expects the acquisition by Avago (AVGO) to go through.
08:16 EDTAGNAllergan's Botox resubmission for lower limb spasticiy accepted by FDA
Allergan 's resubmission of its Supplemental Biologics License Application for Botox for the treatment of adults with lower limb spasticity in adults has been accepted by the FDA. A six-month review period has been assigned for the sBLA. The Prescription Drug User Fee Act date is expected to be in 1Q16. The resubmission provides additional data from a double-blind, placebo controlled study involving 468 patients with lower limb spasticity. The FDA also approved an increase to the maximum Botox cumulative dose within three months from 360 to 400 units in adults treated for one or more indications.
08:03 EDTCNCCentene subsidiary wins statewide foster care contract
Subscribe for More Information
07:00 EDTOISOil States initiated with a Hold at Deutsche Bank
Subscribe for More Information
August 18, 2015
08:27 EDTPHHPHH Corp. price target lowered to $23 from $30 at Sterne Agee CRT
Subscribe for More Information
August 17, 2015
10:55 EDTBRCMOptions with increasing implied volatility
Subscribe for More Information
07:46 EDTTPLMEnerCom to hold a conference
Subscribe for More Information
06:28 EDTGRAW.R. Grace upgraded to Conviction Buy from Buy at Goldman
Goldman added W.R. Grace to the Conviction Buy List to reflect increased confidence a pricing cycle in Catalysts is near and a pricing cycle in Construction remains in its infancy. The firm believes consensus expectations are too low and recent significant customer wins are not fully reflected in 2016 estimates. Shares are Buy rated with a $119 price target on shares.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use